Skip to main content

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.

Publication ,  Journal Article
Moorman, PG; Havrilesky, LJ; Gierisch, JM; Coeytaux, RR; Lowery, WJ; Peragallo Urrutia, R; Dinan, M; McBroom, AJ; Hasselblad, V; Sanders, GD ...
Published in: J Clin Oncol
November 20, 2013

PURPOSE: To estimate the risks of ovarian cancer and breast cancer associated with oral contraceptive (OC) use among women at elevated risk owing to mutations in BRCA1/2 or a strong family history. METHODS: We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published 2000 to 2012 that evaluated associations between OC use and breast or ovarian cancer among women who are carriers of a BRCA1/2 mutation or have a family history of breast or ovarian cancer. RESULTS: From 6,476 unique citations, we identified six studies examining ovarian cancer risk in BRCA1/2 mutation carriers and eight studies examining breast cancer risk in BRCA1/2 mutation carriers. For BRCA1/2 mutation carriers combined, meta-analysis showed an inverse association between OC use and ovarian cancer (odds ratio [OR], 0.58; 95% CI, 0.46 to 0.73) and a nonstatistically significant association with breast cancer (OR, 1.21; 95% CI, 0.93 to 1.58). Findings were similar when examining BRCA1 and BRCA2 mutation carriers separately. Data were inadequate to perform meta-analyses examining duration or timing of use. For women with a family history of ovarian or breast cancer, we identified four studies examining risk for ovarian cancer and three for breast cancer, but differences between studies precluded combining the data for meta-analyses, and no overall pattern could be discerned. CONCLUSION: Our analyses suggest that associations between ever use of OCs and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

November 20, 2013

Volume

31

Issue

33

Start / End Page

4188 / 4198

Location

United States

Related Subject Headings

  • Risk Assessment
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Mutation
  • Humans
  • Heterozygote
  • Female
  • Contraceptives, Oral
  • Breast Neoplasms
  • BRCA2 Protein
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., … Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol, 31(33), 4188–4198. https://doi.org/10.1200/JCO.2013.48.9021
Moorman, Patricia G., Laura J. Havrilesky, Jennifer M. Gierisch, Remy R. Coeytaux, William J. Lowery, Rachel Peragallo Urrutia, Michaela Dinan, et al. “Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.J Clin Oncol 31, no. 33 (November 20, 2013): 4188–98. https://doi.org/10.1200/JCO.2013.48.9021.
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013 Nov 20;31(33):4188–98.
Moorman, Patricia G., et al. “Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.J Clin Oncol, vol. 31, no. 33, Nov. 2013, pp. 4188–98. Pubmed, doi:10.1200/JCO.2013.48.9021.
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013 Nov 20;31(33):4188–4198.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

November 20, 2013

Volume

31

Issue

33

Start / End Page

4188 / 4198

Location

United States

Related Subject Headings

  • Risk Assessment
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Mutation
  • Humans
  • Heterozygote
  • Female
  • Contraceptives, Oral
  • Breast Neoplasms
  • BRCA2 Protein